An immunotherapy candidate for mesothelioma continues to show promise in clinical trials, even before the trial has reached the halfway mark. Norwegian pharmaceutical company Targovax announced updated results Feb. 23 from its ongoing testing of ONCOS-102, a product...

Manufacturing giant Johnson & Johnson has amassed a nearly $4 billion legal reserve to handle thousands of lawsuits, many claiming that its talcum powder products were tainted with asbestos, according to a regulatory filing. The company announced that its consumer...

A planned class-action lawsuit against Johnson & Johnson and Bausch Health over alleged contaminants in their talcum powders — including asbestos — is going to the 9th U.S. Circuit Court of Appeals. An attorney representing the plaintiffs — Louisa Gutierrez and...

A planned study on immunotherapy’s effectiveness in mesothelioma cases got a major cash infusion this week, with the National Cancer Institute agreeing to shell out $2.5 million on the experimental research. Dr. Bryan Burt, who heads up the Baylor College of...

The Food and Drug Administration has granted a potential mesothelioma treatment special status to hasten its approval process. A candidate biologic for first-line treatment of malignant pleural mesothelioma — the most common form of the deadly disease — has been given...

Genetic testing may be the key to distinguishing an unusually aggressive and sneaky type of mesothelioma from an unrelated condition. Chinese researchers have found that a protein emitted by the GATA3 gene is frequently detected in sarcomatoid malignant mesothelioma,...

Mesothelioma’s frequent resistance to chemotherapy may be tied to a genetic mutation in some patients, according to a recent study. Researchers from Switzerland and Germany concluded that pleural mesothelioma patients with a mutated or missing BAP-1 gene all...